About Oxford Immunotec
Oxford Immunotec is a company based in Abingdon (United Kingdom) founded in 2002 was acquired by PerkinElmer in January 2021.. Oxford Immunotec has raised $94 million across 4 funding rounds from investors including Blackstone, New Leaf Venture Partners and Dow. The company has 184 employees as of January 31, 2022. Oxford Immunotec has completed 3 acquisitions, including Boulder Diagnostics, Immunetics and Imugen. Oxford Immunotec offers products and services including T-SPOT.TB, T-SPOT.CMV, T-Cell Select, and Auto-Pure 2400. Oxford Immunotec operates in a competitive market with competitors including Biological Dynamics, OpGen, QuantuMDx, Avails Medical and Resistell, among others.
- Headquarter Abingdon, United Kingdom
- Employees 184 as on 31 Jan, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oxford Immunotec Limited
- Date of Incorporation 21 Aug, 2002
- Jurisdiction ABINGDON, ENGLAND
-
Annual Revenue
$51.81 M (USD)-18as on Dec 31, 2020
-
Net Profit
$-43.54 M (USD)-255as on Dec 31, 2020
-
EBITDA
-
Total Equity Funding
$94 M (USD)
in 4 rounds
-
Latest Funding Round
$325.91 K (USD), Grant
Jan 01, 2018
-
Investors
Blackstone
& 11 more
-
Employee Count
184
as on Jan 31, 2022
-
Investments & Acquisitions
Boulder Diagnostics
& 2 more
-
Acquired by
PerkinElmer
(Jan 07, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oxford Immunotec
Oxford Immunotec offers a comprehensive portfolio of products and services, including T-SPOT.TB, T-SPOT.CMV, T-Cell Select, and Auto-Pure 2400. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Detects latent tuberculosis infections through T-cell immune responses.
Assesses cytomegalovirus in transplant patients via interferon-gamma assay.
Facilitates isolation and preparation of peripheral blood mononuclear cells.
Automates workflows for nucleic acid isolation in pathogen detection.
Unlock access to complete
Funding Insights of Oxford Immunotec
Oxford Immunotec has successfully raised a total of $94M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $325.91 thousand completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $325,910
-
First Round
First Round
(29 Oct 2007)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2018 | Amount | Grant - Oxford Immunotec | Valuation |
investors |
|
| Jun, 2012 | Amount | Series E - Oxford Immunotec | Valuation |
investors |
|
| May, 2010 | Amount | Series D - Oxford Immunotec | Valuation | New Leaf Venture Partners , Kaiser Permanente Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oxford Immunotec
Oxford Immunotec has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, New Leaf Venture Partners and Dow. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in startups are focused on Europe and the US.
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Investments are made in early-stage healthcare startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oxford Immunotec
Oxford Immunotec has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Boulder Diagnostics, Immunetics and Imugen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunoassays for autoimmune and infectious diseases were developed.
|
2009 | ||||
|
Clinical laboratory testing is conducted as a standalone center.
|
1989 | ||||
|
State-of-the-art assay technology for infectious disease diagnosis & pathogen detection. Leading innovator of tests for bacterial, viral, parasitic diseases.
|
1987 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Oxford Immunotec
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oxford Immunotec Comparisons
Competitors of Oxford Immunotec
Oxford Immunotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological Dynamics, OpGen, QuantuMDx, Avails Medical and Resistell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Proprietary lab-on-chip platform for nanoparticle isolation is offered.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
|
|
| domain | founded_year | HQ Location |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| domain | founded_year | HQ Location |
Antibiotic susceptibility testing is provided via bacterial movement detection.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oxford Immunotec
Frequently Asked Questions about Oxford Immunotec
When was Oxford Immunotec founded?
Oxford Immunotec was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Where is Oxford Immunotec located?
Oxford Immunotec is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Is Oxford Immunotec a funded company?
Oxford Immunotec is a funded company, having raised a total of $94M across 4 funding rounds to date. The company's 1st funding round was a Series D of $26M, raised on Oct 29, 2007.
How many employees does Oxford Immunotec have?
As of Jan 31, 2022, the latest employee count at Oxford Immunotec is 184.
What is the annual revenue of Oxford Immunotec?
Annual revenue of Oxford Immunotec is $51.81M as on Dec 31, 2020.
What does Oxford Immunotec do?
Oxford Immunotec was founded in 2002 and is headquartered in Abingdon, United Kingdom. The company operates in the diagnostics sector, focusing on immune-based technologies. A proprietary T-SPOT platform is employed to assess immune cell responses at the single-cell level. Tests are provided for tuberculosis detection, cytomegalovirus monitoring, and evaluating organ rejection risks in transplant patients.
Who are the top competitors of Oxford Immunotec?
Oxford Immunotec's top competitors include QuantuMDx, Avails Medical and OpGen.
What products or services does Oxford Immunotec offer?
Oxford Immunotec offers T-SPOT.TB, T-SPOT.CMV, T-Cell Select, and Auto-Pure 2400.
How many acquisitions has Oxford Immunotec made?
Oxford Immunotec has made 3 acquisitions, including Boulder Diagnostics, Immunetics, and Imugen.
Who are Oxford Immunotec's investors?
Oxford Immunotec has 12 investors. Key investors include Blackstone, New Leaf Venture Partners, Dow, PerkinElmer, and European Union.